Have a feature idea you'd love to see implemented?
Let us know!
ORKA Oruka Therapeutics Inc.
Price (delayed)
$29.89
Market cap
$36.13M
P/E Ratio
N/A
Dividend/share
$19.36
EPS
-$6
Enterprise value
$2.85M
Highlights
The company's debt has shrunk by 100% YoY
The company's quick ratio rose by 15% QoQ and by 4.5% YoY
Oruka Therapeutics's net income has decreased by 20% QoQ and by 14% YoY
Oruka Therapeutics's EPS has decreased by 19% from the previous quarter and by 16% YoY
Key stats
What are the main financial stats of ORKA
Market
Valuations
Earnings
Shares outstanding
1.21M
Market cap
$36.13M
Enterprise value
$2.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$7.2M
EBITDA
-$7.12M
Free cash flow
-$6.89M
Per share
Balance sheet
Liquidity
EPS
-$6
Free cash flow per share
-$5.7
Book value per share
$26.94
Revenue per share
$0
TBVPS
$28
Total assets
$33.84M
Total liabilities
$1.27M
Debt
$0
Equity
$32.57M
Working capital
$32.55M
Debt to equity
0
Current ratio
26.61
Quick ratio
26.19
Net debt/EBITDA
4.68
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-19.5%
Return on equity
-20.2%
Return on invested capital
N/A
Return on capital employed
-22.1%
Return on sales
N/A
Dividend yield
64.76%
DPS
$19.36
Payout ratio
N/A
ORKA stock price
How has the Oruka Therapeutics stock price performed over time
Intraday
-0.99%
1 week
3.03%
1 month
21.6%
1 year
25.8%
YTD
46.52%
QTD
21.95%
Financial performance
How have Oruka Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.13M
Net income
-$7.2M
Gross margin
N/A
Net margin
N/A
Oruka Therapeutics's net income has decreased by 20% QoQ and by 14% YoY
ORKA's operating income is down by 16% year-on-year and by 14% since the previous quarter
Growth
What is Oruka Therapeutics's growth rate over time
Valuation
What is Oruka Therapeutics stock price valuation
P/E
N/A
P/B
1.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Oruka Therapeutics's EPS has decreased by 19% from the previous quarter and by 16% YoY
ORKA's price to book (P/B) is 40% higher than its 5-year quarterly average of 0.8 and 12% higher than its last 4 quarters average of 1.0
The company's equity fell by 17% YoY and by 7% QoQ
Efficiency
How efficient is Oruka Therapeutics business performance
Oruka Therapeutics's return on assets has decreased by 32% YoY and by 26% QoQ
The return on equity has declined by 31% year-on-year and by 25% since the previous quarter
Dividends
What is ORKA's dividend history
DPS
$19.36
Dividend yield
64.76%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Oruka Therapeutics financials performed over time
Oruka Therapeutics's total liabilities has decreased by 31% YoY and by 20% QoQ
The company's total assets fell by 18% YoY and by 8% QoQ
The company's debt is 100% lower than its equity
The company's debt to equity has shrunk by 100% YoY
The company's debt has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.